Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics' stock price has experienced significant movement in the past six months (July 2025 - January 2026). The share price as of January 9, 2026, was $169.38, representing a substantial increase from $80.05 on January 10, 2025. The stock surged after the FDA accepted Axsome's sNDA for AXS-05 in Alzheimer's Disease Agitation with Priority Review. Axsome announced FDA Pre-NDA meeting minutes for AXS-12 in narcolepsy, supporting its NDA submission. Axsome reported its third-quarter 2025 financial results, showcasing strong revenue growth and an agreement to acquire Baergic Bio Inc. B. Riley initiated coverage on Axsome Therapeutics with a "buy" rating and a $179.00 target price. Institutional investors increased their stakes in Axsome Therapeutics. Axsome's Q1 2025 earnings showed a 62% year-over-year increase in total revenue, primarily from Auvelity and Sunosi sales, but demand for Sunosi was adversely impacted by typical seasonality.

Demand for Axsome Therapeutics' products can be subject to seasonality. Total prescriptions for Sunosi in the United States declined sequentially in the first quarter of 2025, as demand was adversely impacted by typical seasonality. Demand for some of their products may fluctuate with the seasons, potentially due to factors like changes in patient behavior or healthcare access during different times of the year.

Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel therapies for central nervous system (CNS) conditions with limited treatment options. The company's business centers on addressing unmet medical needs in CNS disorders. Its commercial products include Auvelity for major depressive disorder (MDD), Alzheimer's disease agitation (AD agitation) and smoking cessation; Sunosi for excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea, also being investigated for other disorders; and Symbravo for the acute treatment of migraine with or without aura in adults. The company also has a late-stage pipeline of product candidates, including AXS-05, AXS-12, AXS-14, and AXS-17.

Axsome Therapeutics is headquartered in New York City, New York, USA. The company operates in the United States, and through licensing agreements, its products like Sunosi are marketed in Europe and certain Middle East/North Africa countries.

Axsome Therapeutics has generally maintained a positive brand reputation over the past year, largely driven by its focus on innovative CNS treatments and regulatory progress. FDA approvals and commercial availability of Auvelity and Symbravo have enhanced Axsome's brand. The FDA's acceptance of the sNDA for AXS-05 in Alzheimer's Disease Agitation with Priority Review in December 2025 was a significant positive event. The company's partnership with Mental Health America in May 2025 contributed positively to its public image. Analyst ratings have largely been positive. In December 2024, Axsome's stock tumbled after mixed results from its Alzheimer's study for AXS-05 were released. Ongoing losses and an accumulated deficit present financial challenges that could impact reputation if not managed effectively.

Axsome Therapeutics, Inc. is primarily owned by institutional shareholders (73.75%) and Axsome Therapeutics insiders (45.75%). Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Wellington Management Group Llp. The largest individual shareholder is Herriot Tabuteau, who owns 14.70 million shares, representing 29.15% of the company. Insiders have sold a significant number of shares in the last three months of 2025.